MetaCap

Rafael Holdings Inc. Class B (RFL)

NYSE: RFLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.9197+0.0197 (+2.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RFL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$47.99M
EPS (TTM)
-$0.58
52-week range
0.781 – 3.96
Day range
0.8001 – 0.9691
Volume / Avg
156.49K / 140.84K
Beta
—
Next earnings
Dec 10, 2026

52-week range

$0.781$3.96

RFL stock today

On Nov 20, RFL ended the session at $0.9197, adding $0.0197 (2.19%), versus the S&P 500's 3.70% decline. At this level, RFL sits near the bottom of its 52-week range of $0.781 to $3.96: 76.8% below the high, set on Jul 1, 2026 and 17.8% above the low. RFL is down 22.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 25.8%.

Rafael has posted a net loss over the last twelve months (EPS of -$0.58), so its P/E ratio is not meaningful. The company is scheduled to report Oct/2026 results on Dec 10.

Summary generated from market data by MetaCap's automated system. Methodology

About Rafael

Company profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Howard S. Jonas
Headquarters
Newark, NJ
Employees
21
IPO year
2018

Financial highlights

Full financials

In fiscal 2026, Rafael generated $874,000 in revenue, down 4.7% from fiscal 2025, its first annual decline since 2023. Rafael reported a net loss of $29.6 million, compared with a loss of $30.5 million a year earlier. Operating margin was -3822.5%.

Rafael annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$874.00K$917.00K$637.00K$279.00K$410.00K
Growth-4.69%+43.96%+128.32%-31.95%-48.88%
Net income$-29.64M$-30.52M$-34.41M$-1.88M$-124.66M
EPS (diluted)$-0.58$-1.04$-1.45$-0.08$-6.31

Earnings

Earnings history
Next report
Dec 10, 2026
Last reported (Jul/2026)
Oct 29, 2026
EPS actual vs est.
$-0.18 vs —

RFL news

All RFL news

Rafael peers

Health Care sector
RFL peer companies
CompanyPrice% ChgMarket capCompare
HRTXHeron Therapeutics Inc.0.2525-4.39%$48.04Mvs RFL
ONCYOncolytics Biotech Inc.0.3501-10.37%$47.66Mvs RFL
NMADNomad Power Solutions Inc.2.56+13.53%$47.15Mvs RFL
VRCAVerrica Pharmaceuticals Inc.2.74-5.03%$47.07Mvs RFL
ACRVAcrivon Therapeutics Inc.1.15-17.86%$49.35Mvs RFL
TNXPTonix Pharmaceuticals Holding Corp.2.38-6.67%$46.25Mvs RFL
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs RFL
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs RFL

Indexes, lists and sector

Rafael stock FAQ

What is Rafael's stock price today?

RFL last traded at $0.9197 as of Nov 20, 4:00 PM EST, up 2.19% on the day. Prices are delayed at least 15 minutes.

Does Rafael pay a dividend?

No. Rafael does not currently pay a regular cash dividend.

When is Rafael's next earnings date?

Rafael is expected to report earnings on Thursday, December 10, 2026.

Who is Rafael's CEO?

Mr. Howard S. Jonas is the chief executive officer of Rafael Holdings Inc. Class B, which has about 21 employees.

Has RFL ever split its stock?

Yes. The most recent RFL stock split was a 1014-for-1000 split on May 9, 2025.

What is the RFL 52-week high?

The 52-week high for RFL is $3.96 and the 52-week low is $0.781. The stock is currently 76.8% below its high.

Compare RFL